Latest news with #GenaWang
Yahoo
9 hours ago
- Business
- Yahoo
Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT
Puma Biotechnology, Inc. (NASDAQ:PBYI) is one of the top most undervalued biotech stocks to buy now. In a report released on August 8, Gena Wang from Barclays maintained a Sell rating on Puma Biotechnology, Inc. (NASDAQ:PBYI) and set a price target of $2.00. A research scientist examining a biological sample to develop a new drug candidate. The rating update came after Puma Biotechnology, Inc. (NASDAQ:PBYI) reported its fiscal Q2 2025 results on August 7. Product revenue net for fiscal Q2 2025 came up to $49.2 million, up from $44.4 million in fiscal Q2 2024. The product revenue net consisted solely of revenue from sales of NERLYNX, which is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) first commercial product. Product revenue net in the first six months of 2025 was $92.3 million, up from $84.6 million in the same time period in 2024. Puma Biotechnology, Inc. (NASDAQ:PBYI) is a biopharmaceutical company involved in the acquisition and development of innovative products to treat different kinds of cancers. The company's focus is on the in-licensing drug candidates that are either in the process of or have already obtained initial clinical testing to treat cancer. It then endeavors to develop these drug candidates further for commercial use. While we acknowledge the potential of PBYI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
23-06-2025
- Business
- Yahoo
Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Gena Wang of Barclays kept BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) at a Buy rating with a price target of $86.00 in a report published on June 10. A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide. According to BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)'s most recent earnings report, the firm made $745.15 million in revenue and $185.69 million in net profit for the quarter that ended on March 31. The company's sales were $648.83 million, and its net profit was $88.66 million last year. It is challenging to avoid past comparisons with Genzyme (bought by Sanofi) as BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) builds a portfolio of genetic-disease therapies. Despite having several authorized treatments, the firm spent years in the red due to commercialization and R&D costs, but analysts are optimistic about the long-term, profitable potential of its present portfolio. It is in a strong position because of its extensive internal pipeline and capacity to add expansion through strategic acquisitions. While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
Business Insider
10-05-2025
- Business
- Business Insider
Barclays Remains a Buy on 4D Molecular Therapeutics (FDMT)
In a report released on May 8, Gena Wang from Barclays maintained a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), with a price target of $38.00. The company's shares closed yesterday at $3.08. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Wang is a 3-star analyst with an average return of 2.3% and a 39.26% success rate. Wang covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Legend Biotech. 4D Molecular Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.14, implying a 975.97% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $26.00 price target. Based on 4D Molecular Therapeutics' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1 thousand and a GAAP net loss of $49.67 million. In comparison, last year the company had a GAAP net loss of $32.28 million
